Every Form 4 that IQVIA Holdings Inc. (IQV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IQV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IQV filings page.
IQVIA HOLDINGS INC. (IQV) executive James G. Berkshire, EVP Global Infrastructure and Operations, reported multiple transactions on September 2, 2026 involving company equity. He exercised stock appreciation rights for 5,381 shares of common stock at an exercise price of $131.82 per share, eliminating this derivative position. On the same date he sold 2,668 shares of common stock at $261.33 per share and disposed of 2,713 shares back to the issuer at $261.54 per share. No transactions are reported as made under a Rule 10b5-1 trading plan.
IQVIA HOLDINGS INC. officer W. Richard Staub reported selling 5,500 shares of Common Stock on 2026-08-03 at $232.68 per share in a sale classified as an open market or private transaction. Following this sale, he directly owns 13,312 shares. The filing does not indicate use of a Rule 10b5-1 trading plan.
IQVIA Holdings Inc. officer Patel Bhavik, President, MedTech and Consumer Health, reported selling 1,855 shares of common stock on July 31, 2026. The sale was at a weighted average price of $235.27 per share, with individual trades between $235.22 and $235.29. Following this transaction, Bhavik directly holds 1,348 shares of IQVIA common stock.
IQVIA Holdings Inc. executive officer Eric Sherbet reported a sale of 5,000 shares of Common Stock on July 29, 2026 at $249.16 per share in a sale characterized as an open market or private transaction. After this transaction, he directly held 20,999 shares.
IQVIA HOLDINGS INC. reported that officer Keriann Cherofsky sold 558 shares of common stock on July 29, 2026 at $245.21 per share in an open-market or private transaction. After this sale, she directly holds 2,989 shares. The trade was not flagged as under a Rule 10b5-1 plan.
Ari Bousbib, Chairman, Chief Executive Officer and President of IQVIA Holdings Inc., exercised stock appreciation rights covering 156,206 shares of common stock on 2026-07-29 at an exercise price of $78.21 per share, from rights expiring on February 2, 2027. On the same date he sold an aggregate 106,279 shares of common stock in open-market transactions at weighted average prices of $247.10, $246.85, $246.08 and $244.78 per share, with individual trade prices ranging from $244.60 to $247.18 as described in the footnotes. He also disposed of 47,858 and 2,069 shares back to the issuer. Following these transactions, 543,302 shares of IQVIA common stock are held indirectly through the Orohena Trust.
IQVIA Holdings Inc. director Wims Morris Leslie received a grant of 148 deferred shares on July 14, 2026 at a reference value of $207.83 per share. Each deferred share converts into one share of common stock upon settlement under the Non-Employee Director Deferral Plan, increasing his deferred-share holdings to 6,784. Settlement generally occurs when he ceases to be a director, upon a change in control, or upon death, and the deferred shares have no expiry date.
IQVIA Holdings Inc. reported that director Colleen A. Goggins received a grant of 183 deferred shares on July 14, 2026. Each deferred share converts into one share of common stock upon settlement when she ceases to be a director, upon a change in control, or upon death. There is no expiry date, and she now holds 5,297 deferred shares directly.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 195 deferred shares on July 14, 2026, at $207.83 per share. Each deferred share is convertible into one share of common stock upon settlement under the Non-Employee Director Deferral Plan, when he ceases to be a director, upon a change in control, or upon death, and there is no expiry date. Following this award, Fasano holds 6,268 deferred shares directly.
DANHAKL JOHN G reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John G. Danhakl received a grant of 160 deferred shares on 2026-07-14, representing rights to an equal number of common shares upon settlement. Under the Non-Employee Director Deferral Plan, these units settle when he leaves the board, upon a change in control, or upon death. Following the award, he holds 3,289 deferred shares directly.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received an award of 171 deferred shares on May 7, 2026. The grant is recorded at a reference price of $178.64 per share and increases his directly held deferred share balance to 6,636 deferred shares.
Each deferred share is convertible into one share of IQVIA common stock upon settlement under the company’s Non-Employee Director Deferral Plan. The deferred shares become settleable when he ceases to be a director, upon a change in control of the company, or upon his death, and there is no expiry date on this award.
IQVIA Holdings Inc. director Colleen A. Goggins received a grant of 214 Deferred Shares on May 7, 2026, as part of her director compensation. Each deferred share is linked to one share of common stock and was valued at $178.64 per deferred share for reporting purposes.
After this grant, Goggins directly holds 5,114 Deferred Shares. These awards convert into common stock upon settlement and become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received an award of 228 deferred shares tied to the company’s common stock. The grant was priced at $178.64 per share and increased his directly held deferred share balance to 6,073.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, these deferred shares become settleable when Fasano ceases to be a director, upon a change in control of the company, or upon his death, and they have no expiry date.
DANHAKL JOHN G reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John G. Danhakl reported a grant of 185 deferred shares on May 7, 2026. These derivative securities were awarded at a reference price of $178.64 per deferred share and increase his directly held deferred share balance to 3,129.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. According to the company’s Non-Employee Director Deferral Plan, the deferred shares become settleable when Danhakl ceases to be a director, upon a change in control of the company, or upon his death, and there is no expiry date.
Stamps Sheila A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Sheila A. Stamps received a grant of 1,571 deferred shares linked to common stock as compensation. The award is priced at $160.68 per deferred share and increases her directly held deferred share balance to 4,210.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, the deferred shares become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received a compensation grant of 1,571 deferred shares on common stock. These deferred shares are convertible into an equal number of IQVIA common shares upon settlement under the company’s Non-Employee Director Deferral Plan.
The award increased the director’s directly held deferred share balance to 6,465. The deferred shares become settleable when the director ceases to serve on the board, upon a change in control of the company, or upon the director’s death, and they do not have an expiry date.
Kaelin William G Jr reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director William G. Kaelin Jr. received a grant of 1,571 deferred shares on April 23, 2026. Each deferred share represents the right to receive one share of IQVIA common stock upon settlement under the company’s Non-Employee Director Deferral Plan.
The deferred shares become settleable when he ceases to be a director, upon a change in control of the company, or upon his death. After this award, he beneficially holds 1,571 deferred shares directly, with no stated expiry date on the award.
LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John M. Leonard reported receiving an equity award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for his role as a non-employee director and are fully vested upon grant, with no purchase price paid. Following this award, Leonard directly holds 16,946 shares of IQVIA common stock.
GOGGINS COLLEEN A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Colleen A. Goggins received an award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for Non-Employee Directors and are fully vested upon grant, bringing her direct holdings to 14,453 shares.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 1,571 deferred shares, each linked to one share of common stock. These deferred shares settle when he ceases to be a director, upon a change in control of the company, or upon his death. Following this award, he holds 5,845 deferred shares in total.
IQVIA HOLDINGS INC. director John G. Danhakl reported an indirect acquisition of 1,571 shares of common stock on an award that was fully vested upon grant for Non-Employee Directors. These shares are held in the Danhakl Revocable Family Trust.
Following the award, the trust holds 30,612 shares of IQVIA common stock, and a related LLC controlled by the trust holds an additional 1,275 shares. The filing reflects compensation-related grants and indirect holdings, not open-market purchases or sales.
Burt Carol reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Carol Burt received an equity award of 1,571 shares of common stock as a non-employee director. The shares were fully vested upon grant and are held indirectly in the Carol Burt Hilliard Revocable Trust, bringing her indirect holdings to 7,533 shares.
Haas Bernd reported disposition transactions in a Form 4 filing for IQV. The filing lists transactions totaling 20 shares at a weighted average price of $166.94 per share. Following the reported transactions, holdings were 24,394 shares.
IQVIA Holdings executive Michael J. Fedock reported a tax-related share disposition. On 02/13/2026, he transferred 123 shares of IQVIA common stock at $166.94 per share to cover tax obligations, as indicated by transaction code “F.” After this tax-withholding disposition, he directly owned 9,472 IQVIA shares.
IQVIA Holdings Inc. reported that executive W. Richard Staub, President of Research & Development Solutions, received a grant of stock appreciation rights covering 26,088 shares of common stock on February 9, 2026. These rights have a $192.67 exercise price and vest in three equal annual installments beginning February 9, 2027.
IQVIA Holdings Inc. reported that executive officer Eric Sherbet, Executive Vice President and General Counsel, was granted a stock appreciation right on its common stock. The award covers 12,112 shares at a conversion or exercise price of $192.67 per share and was granted on February 9, 2026.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027 and expires on February 9, 2036. Following this grant, 12,112 derivative securities tied to IQVIA common stock are beneficially owned directly by the reporting person.
IQVIA Holdings Inc. reported that officer Bhavik Patel, President, MedTech and Consumer Health, received a grant of stock appreciation rights on February 9, 2026. The award covers 11,180 derivative securities tied to 11,180 shares of common stock at a conversion or exercise price of $192.67.
These stock appreciation rights were acquired as a grant or award and are held directly. The award vests in three annual installments beginning on February 9, 2027, meaning the rights become exercisable over a three-year period starting on that date.
IQVIA Holdings Inc. executive Bernd Haas, EVP, AI and Technology Solutions, received a grant of stock appreciation rights on February 9, 2026. The award covers 11,180 stock appreciation rights with a conversion or exercise price of $192.67 per right.
These stock appreciation rights vest in three annual installments beginning on February 9, 2027, and are held as a direct ownership position. After this grant, Haas beneficially owned 11,180 derivative securities tied to IQVIA common stock.
IQVIA Holdings Inc. reported that officer Alistair Grenfell received a grant of 26,088 stock appreciation rights on February 9, 2026, at an exercise price of $192.67 per right. These rights vest in three annual installments beginning on February 9, 2027, and are scheduled to expire on February 9, 2036. Following this award, Grenfell beneficially owns 26,088 derivative securities directly.
IQVIA Holdings executive Michael J. Fedock received a new equity award. On February 9, 2026, he was granted a stock appreciation right covering 18,634 shares of IQVIA common stock at an exercise price of $192.67 per share, expiring on February 9, 2036.
The stock appreciation right was acquired as a grant and is held directly. According to the terms, it will vest in three annual installments beginning on February 9, 2027, aligning the senior vice president of FP&A’s compensation with long-term shareholder value.
IQVIA Holdings Inc. reported that officer Keriann Cherofsky received a grant of stock appreciation rights. On February 9, 2026, she was awarded 2,795 stock appreciation rights with an exercise price of $192.67 per share, held directly.
The grant vests in three equal annual installments beginning on February 9, 2027. After this transaction, Cherofsky beneficially owned 2,795 derivative securities related to IQVIA common stock. She serves as SVP, Corporate Controller.
IQVIA Holdings executive James G. Berkshire received a stock appreciation right award covering 11,180 shares of common stock. The award was granted on February 9, 2026 at an exercise price of $192.67 per share and expires on February 9, 2036.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027. Following this grant, Berkshire beneficially owns 11,180 derivative securities directly, in his role as EVP, Global Infrastructure and Operations.
IQVIA Holdings Inc. Director and Chairman, Chief Executive Officer & President Ari Bousbib reported receiving a grant of stock appreciation rights on February 9, 2026. The award covers 78,264 derivative securities tied to the company’s common stock at a conversion or exercise price of $192.67 per share.
The stock appreciation right vests in three equal annual installments beginning on February 9, 2027, meaning the right becomes exercisable over a three-year period rather than all at once. Following this grant, Bousbib directly holds 78,264 stock appreciation rights related to IQVIA common stock.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Leslie Wims Morris received a grant of 159 deferred share units on February 9, 2026. Each deferred share is convertible into one share of common stock upon settlement under the company’s Non-Employee Director Deferral Plan. Settlement occurs when Morris ceases to be a director, upon a change in control of the company, or upon death, and there is no expiry date. Following this grant, Morris directly beneficially owns 4,894 deferred share units.
IQVIA Holdings Inc. director Colleen A. Goggins received an equity-based award in the form of deferred shares. On 02/09/2026, she acquired 198 deferred shares at a reference price of $192.67 per deferred share, bringing her directly owned deferred share balance to 4,900.
Each deferred share converts into one share of IQVIA common stock upon settlement. According to the company’s Non-Employee Director Deferral Plan, settlement occurs when the director leaves the board, a change in control happens, or upon the director’s death, and the award has no expiry date.
IQVIA Holdings director Jim Fasano reported an acquisition of deferred share units tied to company stock. On 02/09/2026, he received a grant of 211 deferred shares at a reported price of $192.67 per unit, increasing his directly held deferred shares to 4,274.
Each deferred share converts into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, these units generally settle when he ceases to be a director, upon a change in control of the company, or upon his death, and they have no expiration date.
IQVIA Holdings Inc. director John G. Danhakl received a grant of 172 deferred share units on February 9, 2026. The grant is valued at $192.67 per deferred share and increases his directly held deferred shares to 2,944.
Each deferred share converts into one share of IQVIA common stock upon settlement, which occurs under the company’s Non-Employee Director Deferral Plan when he ceases to be a director, upon a change in control of the company, or upon his death. The deferred shares have no expiration date.
IQVIA Holdings executive Bernd Haas reported equity-based compensation activity. On February 8, 2026, he acquired 8,265 shares of common stock at $0 upon achievement of performance goals tied to restricted stock units granted in 2023. The company’s Leadership Development and Compensation Committee certified that these performance conditions were satisfied on that date. On the same day, 440 shares were withheld at a price of $187.49 to cover obligations associated with the award, leaving Haas with 24,414 IQVIA common shares held directly following the transactions. He serves as EVP, AI and Technology Solutions.
IQVIA Holdings Inc. officer Alistair Grenfell reported equity compensation activity involving the company’s common stock. On February 8, 2026, he acquired 11,795 shares of common stock at $0 per share, bringing his holdings to 29,669 shares directly owned.
On the same date, a separate transaction coded F covered the disposition of 5,545 shares at $187.49 per share, after which he directly owned 24,124 shares of IQVIA common stock. The acquired shares were delivered upon achievement of performance conditions under performance-based restricted stock units granted on February 13, 2023.
IQVIA Holdings executive Michael J. Fedock reported equity transactions in company common stock. On February 8, 2026, he acquired 6,735 shares at $0, tied to performance-based restricted stock units whose conditions were confirmed achieved by the Leadership Development and Compensation Committee.
Fedock also disposed of 111 shares on February 7, 2026 and 2,420 shares on February 8, 2026, each at a price of $187.49 per share. After these transactions, he directly beneficially owned 9,595 shares of IQVIA common stock.
IQVIA Holdings officer Bhavik Patel reported equity award activity in company stock. On February 8, 2026, he acquired 4,083 shares of common stock at a price of $0, following satisfaction of performance conditions tied to performance-based restricted stock units granted on February 13, 2023.
On the same date, a separate transaction reduced his direct holdings by 1,920 shares at $187.49 per share, leaving him with 3,203 shares of IQVIA common stock held directly.
IQVIA Holdings executive Eric Sherbet reported equity transactions tied to performance-based awards. On February 8, 2026, he acquired 6,806 shares of common stock at $0, delivered upon the achievement of performance criteria for restricted stock units granted on February 13, 2023.
On the same date, 1,915 shares were disposed of at $187.49 per share, consistent with a share withholding transaction typically used to cover tax obligations. After these transactions, Sherbet directly held 25,999 shares of IQVIA common stock.
IQVIA Holdings executive W. Richard Staub reported two equity-related transactions in common stock on February 8, 2026. He received a grant of 2,722 shares at no cost, reflecting performance-based restricted stock units originally granted on February 13, 2023, after the Leadership Development and Compensation Committee determined the performance conditions were satisfied on February 8, 2026. On the same date, 806 shares were delivered to cover tax obligations at $187.49 per share. Following these transactions, Staub directly holds 18,812 shares of IQVIA common stock.
IQVIA Holdings reported that officer Keriann Cherofsky received 1,087 shares of common stock on February 8, 2026 at $0 per share. These shares were earned after performance conditions tied to performance-based restricted stock units granted on February 13, 2023 were certified as satisfied by the company’s Leadership Development and Compensation Committee.
On the same date, 415 shares of common stock were disposed of at $187.49 per share, leaving Cherofsky with 3,547 shares of IQVIA common stock held directly after the reported transactions.
IQVIA Holdings executive vice president and chief financial officer Ronald E. Bruehlman reported equity transactions in company common stock on February 8, 2026. He acquired 16,335 shares at $0 per share upon achievement of performance criteria tied to performance-based restricted stock units granted on February 13, 2023, after the company’s Leadership Development and Compensation Committee determined those conditions were satisfied.
On the same date, he disposed of 6,801 shares of common stock in a transaction coded “F” at $187.49 per share. Following these transactions, Bruehlman directly owned 44,103 shares of IQVIA common stock and indirectly owned an additional 11,893 shares through the Ronald E. Bruehlman Revocable Trust.
IQVIA Holdings executive James G. Berkshire reported equity compensation activity. On February 8, 2026, he acquired 2,722 shares of common stock at $0.00 per share upon achievement of performance criteria tied to performance-based restricted stock units granted on February 13, 2023.
On the same date, 1,280 shares of common stock were disposed of at $187.49 per share, leaving him with 8,177 shares of IQVIA common stock held directly. The award’s performance conditions were confirmed as satisfied by the company’s Leadership Development and Compensation Committee on February 8, 2026.
IQVIA Holdings Inc. Chairman, Chief Executive Officer & President Ari Bousbib reported equity-related transactions in the company’s common stock on February 8, 2026. He acquired 57,177 shares at $0 when performance conditions on previously granted performance-based restricted stock units were certified as achieved by the Leadership Development and Compensation Committee. On the same day, 28,399 shares were disposed of at $187.49 in a transaction coded “F,” indicating shares were withheld to cover taxes. Following these transactions, he directly owned 835,941 common shares and indirectly held 543,302 shares through the Orohena Trust.
IQVIA Holdings Inc. senior vice president of FP&A Michael J. Fedock reported a disposition of common stock. On 01/28/2026, he disposed of 381 shares of IQVIA common stock at a reported price of $239.76 per share, leaving him with 5,391 shares held directly after the transaction.
IQVIA Holdings insider activity: A senior executive reported several stock transactions in IQVIA Holdings Inc. common stock on 12/18/2025. The filing shows an exercise of 50,000 stock appreciation rights at an exercise price of $59.90 per share, resulting in the acquisition of 50,000 shares of common stock.
On the same date, the executive sold 36,564 shares of common stock in open-market transactions at a weighted average price of $222.43 per share, and a further 13,436 shares at $222.91 per share. Following these transactions, the executive directly owned 807,163 shares of IQVIA common stock and indirectly owned 543,302 shares through the Orohena Trust.
IQVIA (IQV) director Leslie Wims Morris reported acquiring 146 deferred share units on 11/05/2025, coded as an award (A), at a disclosed derivative price of $210.12. Following the transaction, she beneficially owns 4,735 deferred share units, held directly.
Each deferred share converts into one share of common stock upon settlement. Per the plan, settlement occurs when the director service ends, upon a change in control, or upon death; there is no expiration date.